secwatch.observer — SEC 8-K summary
======================================

Issuer:     NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI)
CIK:        0001979414
Form:       8-K
Filed at:   2025-07-25T23:59:59+00:00
Accession:  0001829126-25-005378
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

NeOnc Technologies executes sub-license for NEO100/NEO212 in MENA, milestone toward $50M Quazar deal
--------------------------------------------------------------------------------

- NeOnc executed sub-license agreement with its Abu Dhabi subsidiary NuroCure for NEO100 and NEO212, covering UAE, GCC, and MENA.
- This is the second of five conditions to close a $50M strategic investment from Quazar Investment at $25 per share.
- Proposed structure: 70% of proceeds for NeOnc common stock, 30% for clinical trials and infrastructure in MENA.
- Remaining conditions to be satisfied within 120 days, including legal formation of NuroMENA/NuroCure and finalizing offering documents.
- Management also highlighted recent Russell Microcap Index inclusion as part of its capital markets strategy.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1979414/000182912625005378/0001829126-25-005378-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1979414/000182912625005378/neonctechnologies_8k.htm
  HTML page:      https://secwatch.observer/filing/0001829126-25-005378

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer